Lipid Nanoparticle Composition for Hematopoietic Stem Cell Genome Editing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for genome editing in hematopoietic stem cells, such as electroporation, impose a significant burden on patients and require safer and more efficient in vivo or ex vivo introduction techniques.
Innovation Solution
A drug delivery system using lipid nanoparticles encapsulating genome editing molecules, composed of specific lipid ratios, facilitates targeted gene introduction into hematopoietic stem cells, enabling in vivo genome editing with enhanced safety and efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If electroporation method is used for gene introduction, then gene introduction can be achieved, but patient burden increases and requires ex vivo treatment
Solution Approach 1:
The patent uses lipid nanoparticles as an intermediary carrier to deliver genome editing molecules (such as CRISPR-Cas9 components) directly into hematopoietic stem cells. The lipid nanoparticle structure includes ionizable lipids, PEGylated lipids, and cholesterol, forming a protective vehicle that facilitates in vivo delivery without requiring electroporation or other invasive methods, thereby reducing patient burden while maintaining gene introduction efficiency
Solution Approach 2:
The patent replaces the mechanical electroporation system with a chemical/biological delivery system using lipid nanoparticles. Instead of applying electrical pulses to create temporary pores in cell membranes (mechanical/electrical method), the invention uses biodegradable lipid nanoparticles that fuse with or are endocytosed by cell membranes, enabling gentle in vivo delivery of genome editing molecules
2Productivity
If traditional lipid nanoparticles are used with high cationic lipid content, then gene delivery efficiency improves, but cell toxicity increases
Solution Approach 1:
The patent optimizes the lipid composition parameters by limiting cationic lipid content to 40-60 mol% (rather than higher concentrations), incorporating 10-30 mol% PEGylated lipid to reduce toxicity, and adjusting the ratio of ionizable lipid to cholesterol. These parameter changes maintain sufficient gene delivery efficiency while significantly reducing cell toxicity and improving biocompatibility
Solution Approach 2:
The patent creates a composite lipid nanoparticle system combining multiple lipid types (ionizable lipid, PEGylated lipid, cholesterol) in specific ratios. This composite structure leverages the advantages of each component: ionizable lipids for endosomal escape, PEGylated lipids for steric stabilization and reduced toxicity, and cholesterol for membrane fluidity and nanoparticle stability, achieving balanced delivery efficiency and safety
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system allows for efficient and safe genome editing in hematopoietic stem cells, reducing patient burden by eliminating the need for bone marrow transplantation and improving delivery efficiency compared to existing methods.
Implementation Method 1
a lipid nanoparticle (3) encapsulating the genome editing molecule (2)
Implementation Method 2
the lipid nanoparticle including a lipid membrane (30) having a lumen
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
According to one arrangement, a drug(1) for genetic modification according to an arrangement is a drug for performing genome editing on a gene in a hematopoietic stem cell. The drug for genetic modification contains a genome editing molecule(2) and a lipid nanoparticle(3) encapsulating the genome editing molecule. The lipid nanoparticle includes a lipid membrane(30) having a lumen. The lipid composition contains at least a first lipid (FFT-10) and a second lipid (FFT-20) in the lipid composition. The amount of the second lipid is larger than that of the first lipid, the total amount of the first lipid and the second lipid is 40 mol% or less, and the total amount of the cationic lipid is 60 mol% or less.